Leica Biosystems to Acquire Devicor Medical Products, Inc.

Buffalo Grove, Illinois (ots/PRNewswire) - Leica Biosystems, a global
leader in anatomic pathology laboratory
solutions and instruments, announced today that it has entered into a
definitive agreement to acquire Devicor Medical Products, Inc.

Devicor is a global market leader in breast biopsy instruments and
consumables, with annual revenues of approximately $170 million.
Devicor, headquartered in Cincinnati, Ohio, has more than 550
employees and sells products in more than 50 countries around the
world. It is committed to advancing technology to help clinicians
accurately diagnose breast disease, such as breast cancer, through
minimally invasive procedures.

"Leica Biosystems' products and solutions address the key steps
across the anatomic pathology workflow. The addition of Devicor's
market leading breast biopsy products, especially Mammotome, allows
us to further integrate that workflow from the source, starting with
the patient and the biopsy sample," said Matthias Weber, MD,
President of Leica Biosystems. "This acquisition supports our mission
of advancing cancer diagnostics to improve lives by adding products
that will have direct benefits for the patients and the clinicians
who care for them."

Among Devicor's products is the Original Mammotome Breast Biopsy
System, which, to date, has enabled more than four million women to
have a minimally invasive breast biopsy. Devicor's product portfolio
also includes the Mammotome revolve, the tether-less Mammotome elite,
Neoprobe Gamma Detection System, Mammotome MammoTest stereotactic
biopsy table, as well as a comprehensive portfolio of tissue markers
used in breast disease diagnostic sampling and management.

Devicor will operate as a standalone business within Leica Biosystems
and will continue to be led by Tom Daulton, the current CEO of
Devicor. "Our portfolio of products is highly complementary with
Leica's. We are excited about our future as part of Leica.
Integrating the pathology workflow will open the door to further
improve efficiency, diagnostic quality and patient outcomes," said
Daulton.

The transaction is expected to close in early 2015. The agreement is
subject to applicable regulatory approvals and other customary
closing conditions. No other financial terms and conditions have been
disclosed.

About Leica Biosystems

Leica Biosystems, part of Danaher Corporation's Diagnostics
platform, is a global leader in workflow solutions and automation,
striving to advance cancer diagnostics to improve patients' lives.
Leica Biosystems provides anatomic pathology laboratories and
researchers a comprehensive product range for each step in the
pathology process, from sample preparation and staining to imaging
and reporting. Leica Biosystems' easy-to-use and consistently
reliable offerings help improve workflow efficiency and diagnostic
confidence. The company is represented in over 100 countries. It has
manufacturing facilities in 8 countries, sales and service
organizations in 27 countries, and a network of dealers spanning the
globe. The company is headquartered in Nussloch, Germany. Visit
http://www.LeicaBiosystems.com for more information.

LEICA and the Leica logo are registered trademarks of Leica
Microsystems IR GmbH.

Devicor, Mammotome, Mammotome revolve, Mammotome elite, MammoTest,
and Neoprobe are trademarks of Devicor, Inc.

Contact:

Diane Mielnikowski
Leica Biosystems
Phone: +1-847-257-3111
Email: Diane.Mielnikowski@leicabiosystems.com

ORIGINAL APA-OTS TEXT - THE INFORMATION CONTAINED IN THIS PRESS RELEASE IS SUBJECT TO THE EXCLUSIVE RESPONSIBILITY OF THE ISSUER | PRN

print